Up a level |
(2018) Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. Journal of Pharmacopuncture. pp. 76-81. ISSN 2093-6966
(2016) Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven (TM)) and Activated Prothrombin Complex Concentrates (FEIBA (TM)) to Treat Hemophilia A Patients with Inhibitors in Iran. Iranian Journal of Pharmaceutical Research. pp. 669-677. ISSN 1735-0328